Adalimumab in Crohn's disease

Biologics: Targets and Therapy

Volumn 1, Issue 4, 2007, Pages 355-365

  van Assche, Gert ^a   Vermeire, Séverine ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Biological treatment; Cd; Controlled trial; Inflammatory bowel diseases; Medical treatment; Uc

Indexed keywords

EID: 79955806569     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Anderson PJ. 2005. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum, 34(S1):19-22.
2. Askling J, Brandt L, Lapidus A, et al. 2005. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut, 54:617-22.
3. Baert F, Noman M, Vermeire S, et al. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med, 348:601-8
4. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. 2007. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis, 66:921-6.
5. Beaugerie L, Seksik P, Nion-Larmurier I, et al. 2006. Predictors of Crohn's disease. Gastroenterology, 130:650-6.
6. Bongartz T, Sutton AJ, Sweeting MJ, et al. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, 295:2275-85.
7. Colombel J, Sandborn WJ, Rutgeerts P. et al. 2007. Adalimumab induces and maintains clinical response and remission in patients with active Crohn's disease: the CHARM trial. Gastroenterology, 132:52-65.
8. Colombel JF, Sandborn WS, Reinisch W et al. 2007. Adalimumab safety in Crohn's disease clinical trials. Gastroenterology, 132:A-504.
9. Cornillie F, Shealy D, D'Haens G, et al. 2001. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther, 15:463-73.
10. Di Sabatino A, Ciccocioppo R, Cinque B, et al. 2004. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut, 53:70-7.
11. Farrell RJ, Alsahli M, Jeen YT, et al. 2003. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology, 124:917-24.
12. Hanauer S, Lukáš M, MacIntosh D, et al. 2006. A randomized, double-blind, placebo-controlled trial of the human anti-TNF-a monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. Gastroenterology, 130:323-33.
13. Hanauer SB, Feagan BG, Lichtenstein GR, et al. 2002. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet, 359:1541-9.
14. Hanauer SB, Wagner CL, Bala M, et al. 2004. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol, 2:542-53.
15. Hinojosa J, Gomollon F, Garcia S, et al. 2007. Spanish Scientific Group on Crohn's Disease and Ulcerative Colitis. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther, 25:409-18.
16. Hommes D, Baert F, Van Assche G. et al. 2006. The ideal management of Crohn's disease: top down versus step up strategies, a randomized controlled trial [abstract]. Gastroenterology, 130:A108.
17. Hommes D, van den Blink B, Plasse T, et al. 2002. Inhibition of stressactivated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology, 122:7-14.
18. Hwang WYK, Foote J. 2005. Immunogenicity of engineered antibodies. Methods, 36:3-10.
19. Keane J, Gershon S, Wise RP, et al. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med, 345:1098-104.
20. Lichtenstein GR, Feagan BG, Cohen RD, et al. 2006. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol, 4:621-30.
21. Listing J, Strangfeld A, Kary S, et al. 2005. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum, 52:3403-12.
22. Lugering A, Schmidt M, Lugering N, et al. 2001. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology, 121:1145-57.
23. Munkholm P, Langholz E, Davidsen M, et al. 1994. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut, 35:360-2.
24. Nesbitt A, Fossati G, Bergin M, et al. 2007. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis, 13:323-32.
25. Osbourn J, Groves M, Vaughan T. 2005. From rodent reagents to human therapeutics using antibody guided selection. Methods, 36:61-8.
26. Peyrin-Biroulet L, Laclotte C, Roblin X, et al. 2007. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study. World J Gastroenterol, 13:2328-32.
27. Podolsky DK. 2002. Inflammatory bowel disease. N Engl J Med, 347:417-29.
28. Present DH, Rutgeerts P, Targan S, et al. 1999. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med, 340:1398-405.
29. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. 2004. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology, 126:402-13.
30. Rutgeerts P., Sandborn WJ, Fedorak RN, et al. 2006. Onercept for moderateto-severe Crohn's disease: a randomized, doubl-blind, placebocontrolled trial. Clin Gastroenterol Hepatol, 4:888-93.
31. Salfield J, Allen D, Hoogenboom H, et al. 2000. BASF Aktiengesellschaft, assignee. Human antibodies that bind human TNF alpha. US patent 6,090,382.
32. Sandborn WJ, Feagan BG, Stoinov S, et al. 2006. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26 week placebo-controlled phase III study (PRECiSe 1). Gastroenterology, 130:A-107.
33. Sandborn WJ, Hanauer S, Loftus EV Jr, et al. 2004. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol, 99:1984-9.
34. Sandborn WJ, Hanauer SB, Katz S, et al. 2001. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology, 121:1088-94.
35. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. 2007. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II Trial. Gut, 56:1232-9.
36. Sandborn WJ, Rutgeerts P, Enns R, et al. 2007. Adalimumab induction therapy for Crohn's disease previously treated with infliximab. Ann Int Medicine, 146:I20.
37. Sandborn WJ, Feagan BG, Stoinov S, et al.; PRECISE 1 Study Investigators. 2007. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med, 357:228-38.
38. Sands BE, Anderson FH, Bernstein CN, et al. 2004. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med, 350:876-85.
39. Schiff MH, Burmester GR, Kent JD, et al. 2006. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis, 65:889-94.
40. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. 2007. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med, 357:239-50.
41. Schreiber S, Rutgeerts P, Fedorak RN, et al. 2005. A randomized, placebocontrolled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology, 129:807-18.
42. Shen C, Van Assche G, Colpaert S, et al. 2005. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther, 21:251-8.
43. Shen C, Van Assche G, Rutgeerts P, et al. 2006. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis, 12:22-8
44. Siemanowski B, Kip K, Plevy S, et al. 2006. Adjustment in infliximab dose or dosing interval in Crohn's disease. Experience from the University of Pittsburgh. Gastroenterology, 130:A-142.
45. Targan SR, Hanauer SB, van Deventer SJ, et al. 1997. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med, 337:1029-35.
46. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. 2002. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut, 50:206-11.
47. Travis SP, RDP Investigators' Study Group, Yap L,. 2003. RDP58-a novel and effective oral therapy for ulcerative colitis (UC) results of parallel prospective, multicentre, blinded placebo-controlled trials. Gut, 52(SVI):A5.
48. Van Assche G, Painteaud G, D'Haens G, et al. 2006. Continuation of immunomodulators is not required to maintain adequate infliximab efficacy in patients with Crohn's disease but may improve pharmacokinetics. Gastroenterology, 130:A-142.
49. van den Brande JM, Braat H, van den Brink GR, et al. 2003. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology, 124:1774-85.
50. Vermeire S, Noman M, Van Assche G, et al. 2003. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology, 125:32-9.
51. Wallis RS, Broder M, Wong J, et al. 2005. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis, 41:S194-8.
52. Weinblatt ME, Keystone EC, Furst DE, et al. 2003.Adalimumab a fully human anti-tumor necrosis factorα monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA Trial. Arthritis Rheum, 48:35-45.
53. Wolfe F, Michaud K. 2007. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum, 56:1433-9.
54. Youdim A, Vasiliauskas EA, Targan SR, et al. 2004. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis, 10:333-8.